The purpose of the study is to assess how safe and feasible it is to use these treatments alternately in patients who have already received curative therapy, such as surgery or radiation, for their prostate cancer. Participants will receive these treatments in a specific sequence, and the study will monitor how well they tolerate the treatments and any side effects they may experience. The study will also look at how these treatments affect the patients’ quality of life and the progression of their cancer over time.

Throughout the study, participants will undergo regular assessments to check their health and the status of their cancer. This includes monitoring their prostate-specific antigen (PSA) levels, which is a marker used to track prostate cancer, and using imaging tests like PET/CT scans to see how the cancer responds to the treatment. The study aims to provide valuable information on the potential benefits and risks of using these radioligand therapies in treating prostate cancer that has spread to the bones.

Participants in the study will receive the combination of radiotherapy and pembrolizumab. The treatment involves pembrolizumab being given as an infusion, which means it is administered directly into the bloodstream through a vein. The study will monitor participants over a period to see how their PSA levels respond to the treatment and to check for any side effects. The goal is to see if the treatment can lower PSA levels to undetectable amounts and to observe how long patients can go without the cancer progressing.

The study will also look at other factors, such as how long patients can remain free from cancer progression and the overall impact on their quality of life. This will help researchers understand the potential benefits of using pembrolizumab in combination with radiotherapy for treating recurrent prostate cancer. Participants will be closely monitored throughout the study to ensure their safety and to gather important information about the treatment’s effects.

Participants in the study will receive either the combination of Apalutamide, radiotherapy, and LHRH agonist or just radiotherapy and LHRH agonist. The study will also include an observational group to gather additional information. Apalutamide is taken as a tablet by mouth, while radiotherapy is a treatment that uses high-energy rays to target cancer cells. The LHRH agonist is a type of hormone therapy that is given as an injection under the skin. The study will monitor participants over a period to observe the effects of the treatments.

The study aims to provide valuable insights into whether adding Apalutamide can improve outcomes for patients with high-risk hormone-sensitive prostate cancer. By using PSMA-PET, a type of imaging that helps visualize prostate cancer, researchers hope to better understand how the cancer responds to the treatment. This trial is an important step in exploring new ways to manage and treat prostate cancer effectively.

Participants in the study will receive the treatment, which involves the use of the SpectraCure P18 System to deliver light directly to the cancer cells. This is done to help eliminate the cancer cells in the prostate. The study will also determine the safest and most effective doses of both the drug and the light used in the treatment. The treatment is administered through a process called infusion, where the medication is delivered directly into the bloodstream.

The study will monitor participants over a period of time to evaluate the treatment’s impact on the cancer and any side effects that may occur. The effectiveness of the treatment will be assessed using imaging techniques like MRI to see how well the cancer responds. The goal is to find out if this new approach can safely and effectively treat recurrent prostate cancer, providing a potential new option for patients facing this condition.

Participants in the study will receive either the standard radiotherapy or the individualized treatment. The individualized treatment involves using a special solution called 18F-PSMA-1007, which is injected into the body to help highlight cancer cells during the PSMA PET/CT scan. Another product used in the study is the Locametz 25 micrograms kit for radiopharmaceutical preparation, which contains a substance called gozetotide. Both treatments are administered through an injection into a vein.

The purpose of the study is to determine which treatment approach is more effective in preventing the progression of prostate cancer, as measured by PSA levels. Participants will be monitored over time to assess their response to treatment, including how long it takes for the cancer to spread, their overall survival, and their quality of life. The study will also track the time until any additional treatments are needed. This research is expected to provide valuable insights into the best ways to manage prostate cancer recurrence after surgery.

The purpose of the study is to determine if the combination of darolutamide and ADT, given over a period of 24 months, can improve a specific measure of cancer progression when compared to a placebo and ADT. During the study, participants will receive either the active treatment or a placebo, and their progress will be monitored using a special imaging technique called PSMA PET/CT. This imaging method helps to identify cancerous lesions in the body. The study will last for a total of 24 months, and participants will undergo regular assessments to track their response to the treatment.

In addition to darolutamide, the study will also use imaging agents such as Gallium (68Ga) PSMA-11 (gozetotide) and Piflufolastat (18F) to assist in the PSMA PET/CT scans. These agents help to highlight cancer cells during the imaging process, making it easier to assess the effectiveness of the treatment. The trial aims to provide valuable insights into whether this combination therapy can offer better outcomes for patients with high-risk prostate cancer recurrence.

Participants in the study will receive either atorvastatin, a cholesterol-lowering drug, or a placebo, which is an identical capsule without any active ingredient. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This approach helps ensure that the results are not influenced by expectations or bias. The trial will monitor the time it takes for the disease to progress after starting ADT or antiandrogen therapy.

The study will take place over a period of time, with regular check-ups to assess the health and progress of the participants. The goal is to gather information on whether atorvastatin can be an effective addition to the treatment of prostate cancer, potentially offering a new way to manage the disease and improve patient outcomes. Participants will be closely monitored throughout the study to ensure their safety and well-being.